Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Theravance Biopharma Analyst Ratings and Price Targets | NASDAQ:TBPH | Benzinga
Theravance Biopharma Inc has a consensus price target of $13.17 based on the ratings of 6 analysts. The high is $21 issued by BTIG on April 12, 2024. The low is $9 issued by TD Cowen on August 6, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on February 27, 2025, February 25, 2025, and September 16, 2024, respectively. With an average price target of $15 between HC Wainwright & Co., there's an implied 61.12% upside for Theravance Biopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
TD Cowen
Leerink Partners
BTIG
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for Theravance Biopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/27/2025 | Buy Now | 61.12% | HC Wainwright & Co. | Douglas Tsao50% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 02/25/2025 | Buy Now | 61.12% | HC Wainwright & Co. | Douglas Tsao50% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 61.12% | HC Wainwright & Co. | Douglas Tsao50% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/06/2024 | Buy Now | 61.12% | HC Wainwright & Co. | Douglas Tsao50% | $20 → $15 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | -3.33% | TD Cowen | Marc Frahm28% | $10 → $9 | Maintains | Hold | Get Alert |
| 08/06/2024 | Buy Now | 7.41% | Leerink Partners | David Risinger6% | $15 → $10 | Downgrade | Outperform → Market Perform | Get Alert |
| 05/29/2024 | Buy Now | 114.82% | HC Wainwright & Co. | Douglas Tsao50% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 114.82% | HC Wainwright & Co. | Douglas Tsao50% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 04/12/2024 | Buy Now | 125.56% | BTIG | Julian Harrison41% | → $21 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | 114.82% | HC Wainwright & Co. | Douglas Tsao50% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2023 | Buy Now | 114.82% | HC Wainwright & Co. | Douglas Tsao50% | $19 → $20 | Maintains | Buy | Get Alert |
| 02/28/2023 | Buy Now | 104.08% | HC Wainwright & Co. | Douglas Tsao50% | → $19 | Reiterates | → Buy | Get Alert |
| 11/17/2022 | Buy Now | 50.38% | SVB Leerink | David Risinger6% | $12 → $14 | Maintains | Outperform | Get Alert |
| 11/08/2022 | Buy Now | 104.08% | HC Wainwright & Co. | Douglas Tsao50% | $12 → $19 | Maintains | Buy | Get Alert |
| 07/25/2022 | Buy Now | 7.41% | Morgan Stanley | Vikram Purohit37% | $11 → $10 | Maintains | Underweight | Get Alert |
| 05/23/2022 | Buy Now | 28.89% | SVB Leerink | David Risinger6% | → $12 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Theravance Biopharma (TBPH) stock?
The latest price target for Theravance Biopharma (NASDAQ:TBPH) was reported by HC Wainwright & Co. on February 27, 2025. The analyst firm set a price target for $15.00 expecting TBPH to rise to within 12 months (a possible 61.12% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Theravance Biopharma (TBPH)?
The latest analyst rating for Theravance Biopharma (NASDAQ:TBPH) was provided by HC Wainwright & Co., and Theravance Biopharma reiterated their buy rating.
When was the last upgrade for Theravance Biopharma (TBPH)?
There is no last upgrade for Theravance Biopharma
When was the last downgrade for Theravance Biopharma (TBPH)?
The last downgrade for Theravance Biopharma Inc happened on August 6, 2024 when Leerink Partners changed their price target from $15 to $10 for Theravance Biopharma Inc.
When is the next analyst rating going to be posted or updated for Theravance Biopharma (TBPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theravance Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theravance Biopharma was filed on February 27, 2025 so you should expect the next rating to be made available sometime around February 27, 2026.
Is the Analyst Rating Theravance Biopharma (TBPH) correct?
While ratings are subjective and will change, the latest Theravance Biopharma (TBPH) rating was a reiterated with a price target of $15.00 to $15.00. The current price Theravance Biopharma (TBPH) is trading at is $9.31, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
